Moderna’s new Covid vaccine generated a strong immune response against BA.2.86, a highly mutated omicron variant that health officials are watching closely, according to clinical trial data the biotech company released Wednesday.
Moderna, Pfizer and Novavax are slated to roll out new vaccines targeting another omicron strain, pending potential approvals from the FDA.
Moderna’s new trial results suggest that the company’s jab will still be effective against newer variants of the virus, even as XBB.1.5 declines nationwide.
